Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$1.00 USD
-0.03 (-2.44%)
Updated Aug 4, 2025 03:59 PM ET
After-Market: $1.01 +0.01 (1.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CMMB 1.00 -0.03(-2.44%)
Will CMMB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMMB
KURA Stock Rises More Than 15% This Past Week: Here's Why
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
CMMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Other News for CMMB
Chemomab Therapeutics management to meet with Maxim
CMMB: Upcoming Meeting Hosted by Maxim on August 7-8
Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug
Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Chemomab Therapeutics (CMMB)
CMMB Advances Toward Phase 3 with FDA Approval on Key Milestones | CMMB Stock News